A current overview of corticosteroid use in active ulcerative colitis
| Autor: | Fernando Rizzello, Carlo Calabrese, L. Calandrini, Marco Salice, Paolo Gionchetti |
|---|---|
| Přispěvatelé: | Salice M., Rizzello F., Calabrese C., Calandrini L., Gionchetti P. |
| Rok vydání: | 2019 |
| Předmět: |
safety
corticosteroid medicine.medical_specialty Adrenal cortex hormones IBD Treatment outcome Anti-Inflammatory Agents Mucosal inflammation Adrenal Cortex Hormone Gastroenterology Biological drugs 03 medical and health sciences 0302 clinical medicine Gastrointestinal Agents Adrenal Cortex Hormones Internal medicine Gastrointestinal Agent medicine Humans therapy Gastrointestinal agent Ulcerative coliti Hepatology business.industry medicine.disease Ulcerative colitis digestive system diseases Anti-Inflammatory Agent Treatment Outcome 030220 oncology & carcinogenesis Colitis Ulcerative 030211 gastroenterology & hepatology Corticosteroid use business Human |
| Zdroj: | Expert Review of Gastroenterology & Hepatology. 13:557-561 |
| ISSN: | 1747-4132 1747-4124 |
| DOI: | 10.1080/17474124.2019.1604219 |
| Popis: | Introduction: Ulcerative colitis (UC) is a chronic inflammatory condition that causes continuous mucosal inflammation of the colon. New biological drugs have been developed in order to avoid colectomy, but corticosteroids still play a crucial role in management of active UC. Areas covered: We reviewed the current literature about the importance of corticosteroid use in the treatment of ulcerative colitis. The evidence reviewed in this article is a summation of relevant scientific publications, expert opinion statements, and current practice guidelines. This review is a summary of expert opinion in the field without a formal systematic review of evidence. Expert opinion: Corticosteroids represent the mainstay of treatment in patients with severe UC and are very effective in inducing remission in mild to moderate flares not responding to combined oral and topical mesalazine. A valid alternative to systemic corticosteroids is represented by poorly absorbed steroids, such as Beclomethasone dipropionate and Budesonide MMX. In mild-moderate distal disease topical administration of corticosteroids (both systemic and BDP) is an effective alternative to topical mesalazine. However, corticosteroids do not represent a therapeutic option as a maintenance treatment since they are associated with multiple adverse effects. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|